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OBJECTIVE — To examine usual marine -3 fatty acid (mO-3FA) intake in individuals with
diabetes; its association with adiposity, lipid, and glucose control; and its changes with behav-
ioral lifestyle intervention for weight loss.
RESEARCH DESIGN AND METHODS — Cross-sectional and 1-year longitudinal
analyses were performed on 2,397 Look AHEAD (Action for Health in Diabetes) participants.
Look AHEAD is a cardiovascular outcome trial evaluating the effects of intensive lifestyle inter-
vention for weight loss in overweight/obese subjects with type 2 diabetes.
RESULTS — BaselinemO-3FAintakewas162138mg/day.Itwasinverselyassociatedwith
triglycerides ( 0.41, P  0.001) and weakly with HDL (4.14, P  0.050), after
multiplecovariateadjustment.One-yearmO-3FAandfried/sandwichﬁshintakedecreasedwith
intensive lifestyle intervention (P  0.001).
CONCLUSIONS — mO-3FA intake in Look AHEAD participants was low but associated
favorably with lipids. These results encourage investigation on the potential beneﬁts of increas-
ing mO-3FA intake in lifestyle interventions for weight loss in individuals with diabetes.
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O
bservational studies have suggested
that marine -3 fatty acid (mO-
3FA) intake may decrease coronary
atherosclerosis progression in subjects
with diabetes (1). However, only a frac-
tion of participants in cardiovascular
event studies have had diabetes. Con-
cerns that high-dose mO-3FAs may
worsen glucose control have reduced en-
thusiasm for their use in diabetes (2). Lit-
tle is known regarding usual dietary mO-
3FA intake and its association with
metabolic disturbances in diabetes, and
much less is known about the effects of
weight loss interventions on mO-3FA
consumption.
RESEARCH DESIGN AND
METHODS— A total of 2,397 partic-
ipants, corresponding to the ﬁrst half of
Look AHEAD (Action for Health in Dia-
betes) enrollees, completed the Look
AHEAD food frequency questionnaire
(LA-FFQ) (3). Look AHEAD is a multi-
center randomized trial in overweight/
obese individuals with type 2 diabetes,
investigating the effects of intensive life-
styleintervention–inducedweightlosson
cardiovascular morbidity and mortality.
Eligibility criteria included BMI 25
kg/m
2 (27 kg/m
2 if on insulin), age
45–76 years, A1C 11%, blood pressure
160/100 mmHg, and fasting triglycer-
ides 600 mg/dl (4).
The LA-FFQ and its analysis were
previously described (3). Eight line items
inquireaboutseafoodconsumption.mO-
3FA intake was estimated by adding eico-
sapentaenoic acid and docosahexaenoic
acid intake from the LA-FFQ.
Statistical analysis
The baseline association between mO-
3FA intake and weight, BMI, waist cir-
cumference, A1C, fasting glucose, and
lipids was examined using multiple-
variablelinearregression.Theﬁnalmodel
included demographics, dietary vari-
ables, ﬁtness (exercise capacity on graded
exercise test), and class use of medica-
tions to control lipids and glucose. Com-
parisons between race/ethnicity groups
weretestedwithANCOVA.Differencesin
variable change at 1 year between inten-
sive lifestyle intervention and the usual-
care group (diabetes, support, and
education) were analyzed with an un-
paired t test and 
2 test. Data were avail-
able for each variable analyzed in 99%
of participants. An 0.05 indicated
signiﬁcance.
RESULTS— Participant baseline
characteristics do not differ from those
of the overall Look AHEAD sample (5)
with respect to sex, race/ethnicity, adipos-
ity,orﬁtness.Agecriteriachangeduringthe
secondyearofstudyrecruitmentresultedin
a slightly younger age in our subgroup (see
Table S1, available in an online appen-
dix at http://care.diabetesjournals.org/
cgi/content/full/dc09-1235/DC1).
mO-3FA intake and metabolic
variables at baseline
MeanmO-3FAintakewas162138mg/
day (median 120 mg/day). Intake was
200 mg/day in 75% of Look AHEAD
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1%, with signiﬁcant race/ethnicity dif-
ferences (Table 1). mO-3FA intake was in-
versely associated with triglycerides (log-
transformed) ( 0.41, P  0.001)
and with a trend for increasing HDL (
4.14, P  0.050), independently of mul-
tiplecovariates(TableS2).Noassociation
was found between mO-3FA intake and
eachofcholesterol,non-HDLorLDLcho-
lesterol, markers of adiposity, or glucose
control (P 	 0.05). African Americans,
who consumed the most mO-3FAs, had
the highest HDL cholesterol and the low-
est triglycerides.
mO-3FA intake and HDL and
triglyceride levels with intensive
lifestyle intervention at 1 year
mO-3FA intake decreased with intensive
lifestyle intervention but not with diabe-
tes, support, and education at 1 year (P 
0.001) (Table 1). When investigating
changes in type of ﬁsh consumed, we
found an intensive lifestyle intervention–
induced decrease in fried/sandwich ﬁsh
consumption (P  0.001) but not in lean
ormO-3FA–richﬁsh.Thesmallchangein
mO-3FAintakewithintensivelifestylein-
tervention did not explain 1-year changes
in HDL and triglycerides.
CONCLUSIONS— LookAHEADof-
fers a large sample of individuals with di-
abetes in whom a validated tool was used
to estimate usual mO-3FA intake. mO-
3FA consumption was found to be very
low. An intake of 1,000 mg/day is rec-
ommended for people with diabetes (6–
8). Despite the low levels, mO-3FA
consumption was associated with lower
triglycerides and with a trend for higher
HDL.TherelationshipbetweenmO-3FAs
and each of HDL and triglycerides was
independent of adiposity, ﬁtness, lipid
medications (including ﬁbrates), glyce-
mic control, and dietary variables that af-
fect lipid levels, such as carbohydrate,
ﬁber, and saturated fat. Likewise, the in-
take of linolenic acid, a precursor of eico-
sapentaenoic acid and docosahexaenoic
acid, and consumption of its metabolic
competitor linoleic acid, did not alter the
relationship between mO-3FA intake and
HDL and triglycerides.
Contrary to reports with high-dose
mO-3FA (9,10), we did not ﬁnd an unfa-
vorable association between mO-3FA
consumption and LDL cholesterol or glu-
cose control. These ﬁndings encourage
future outcome studies in individuals
with diabetes evaluating lower intakes of
mO-3FA than those previously investi-
gated. A large trial with eicosapentaenoic
acid supplementation in high-risk sub-
jects found the greatest reduction in car-
diovascular events in the subgroup with
lower HDL and higher triglycerides (11),
raising the possibility that mO-3FA may
be of a particular beneﬁt in individuals
with diabetes, who characteristically dis-
play this lipid proﬁle. The race/ethnicity
differences in mO-3FA consumption and
the question of whether speciﬁc groups
might speciﬁcally beneﬁt from interven-
tions that increase mO-3FA intake are
worthy of further study.
ThedecreaseinmO-3FAswithinten-
sivelifestyleinterventionisnotsurprising
given that the Look AHEAD intervention
was not targeted at increasing mO-3FA
intake. The decrease in mO-3FA intake
paralleled a reduction in fried/sandwich
ﬁsh intake, which is considered favorable
(12).
Our results should be interpreted
with caution. Look AHEAD did not eval-
uate supplement use and is subject to the
limitations of information obtained by
self-report (3). The favorable association
between usual dietary mO-3FA intake
and lipids at baseline encourages future
research on the potential beneﬁt of in-
creasing consumption of mO-3FAs, in
addition to modifying ﬁsh type, when
planninglifestyleinterventionsforweight
loss in individuals with diabetes.
Acknowledgments— This study was sup-
portedbytheNationalHeart,Lung,andBlood
Institute Grants 3R01 HL090514-02S1 (to
L.M.B.) and HL090514 (to C.M.B.). The Look
AHEAD study is sponsored by the National
Institute of Diabetes and Digestive and Kidney
Diseases and cosponsored by the National
Heart, Lung and Blood Institute, the National
InstituteofNursingResearch,theOfﬁceofRe-
search on Women’s Health, the National Cen-
ter on Minority Health and Health Disparities,
and the Centers for Disease Control and Pre-
vention. A complete list of contributors and
resource centers may be found in Ref. 5.
D.C.S. has received research support from
TakedaPharmaceuticals.C.M.B.hasactedasa
consultant to and speaker for GlaxoSmith-
Kline. No other potential conﬂicts of interest
relevant to this article were reported.
Parts of this study were presented in ab-
stract form at the 69th Scientiﬁc Sessions of
the American Diabetes Association, New Or-
leans, Louisiana, 5–9 June 2009.
Table1—DietaryintakeofmO-3FAsandfriedﬁshandHDLandtriglyceridelevelsatbaseline
and 1 year
mO-3FA
(mg/day)
HDL
(mg/dl)
Triglycerides
(mg/dl)
Subjects with fried
ﬁsh/sandwich ﬁsh
intake 1/week
(%)
Baseline
Overall (n  2,397) 162 (138) 43 (11.3) 186 (125.6)
African American (n  331) 205 (186)* 48.2 (13.0)* 127.4 (99.8)*
Caucasian (n  1,552) 160 (130) 41.4 (10.7) 197.6 (127.01)
Other (n  76) 156 (117) 45.0 (12.1) 156.7 (90.7)
Hispanic (n  316) 152 (115) 42.4 (10.8) 191.7 (119.7)
Native American (n  122) 98 (117) 40.9 (9.0) 192.7 (156.1)
Longitudinal
ILI (n  1,211)
Baseline 160 (145) 43 (11.2) 189 (127.4) 5.62
Change at 1 year 20 (137)† 3.5 (7.1)† 34.9 (11.5)† 3.56‡
DSE (n  1,186)
Baseline 160 (129) 42 (11.3) 182 (123.6) 6.16
Change at 1 year 0 (121) 1.4 (6.6) 14.7 (98.7) 0.93
*Differences across race/ethnicity groups were tested by ANOVA after adjusting for age, sex, and clinic site.
African Americans had higher intake of mO-3FA, higher HDL, and lower triglycerides than Caucasians,
Hispanics, and the other race/ethnicity group (P  0.05 for all differences). †Differences between intensive
lifestyleintervention(ILI)anddiabetes,support,andeducation(DSE)invariablechangefrombaselinewere
evaluatedusingtheunpairedttest.ILIparticipantshadlowermO-3FAs,higherHDL,andlowertriglycerides
than individuals in DSE (P  0.001 for all differences). ‡Differences between ILI and DSE in the proportion
ofsubjectseatingfriedﬁsh/sandwichﬁsh1/weekweretestedwith
2.Therewasagreaterdecreaseoffried
ﬁsh/sandwichﬁshintakeinILIthaninDSE(P0.001).Percentsubjectseatingleanﬁsh	1/weekincreased
by 5.54% with ILI and by 1.27% with DSE (P  0.012). Change in percent subjects eating ﬁsh rich in
mO-3FAs did not differ between ILI and DSE at 1 year (P  0.421).
Marine -3 fatty acid intake in Look AHEAD
198 DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 care.diabetesjournals.orgAPPENDIX— Members of the Look
AHEAD Obesity, Inﬂammation, and
Thrombosis Research Group include
Christie M. Ballantyne, MD; L. Maria
Belalcazar, MD; Elaine S. Cornell, BS;
Steven F. Haffner, MD; Ron C. Hoo-
geveen,PhD;AndreaKriska,PhD;Santica
M. Marcovina, PhD; Elizabeth Mayer-
Davis, PhD; F. Xavier Pi-Sunyer, MD;
David M. Reboussin, PhD; Rebecca S.
Reeves, DrPh; Charles E. Rhodes, BS;
Dawn C. Schwenke, PhD; and Russell P.
Tracy, PhD.
References
1. Erkkila ¨ AT, Lichtenstein AH, Mozaffarian
D, Herrington DM. Fish intake is asso-
ciated with a reduced progression of
coronary artery atherosclerosis in post-
menopausal women with coronary ar-
tery disease. Am J Clin Nutr 2004;80:
626–632
2. Glauber H, Wallace P, Griver K, Brechtel
G. Adverse metabolic effect of omega-3
fatty acids in non-insulin-dependent dia-
betesmellitus.AnnInternMed1988;108:
663–668
3. Vitolins MZ, Anderson AM, Delahanty L,
RaynorH,MillerGD,MobleyC,ReevesR,
Yamamoto M, Champagne C, Wing RR,
Mayer-Davis E; Look AHEAD Research
Group. Action for Health in Diabetes
(Look AHEAD) trial: baseline evaluation
of selected nutrients and food group in-
take. J Am Diet Assoc 2009;109:1367–
1375
4. Ryan DH, Espeland MA, Foster GD,
Haffner SM, Hubbard VS, Johnson KC,
Kahn SE, Knowler WC, Yanovski SZ;
Look AHEAD Research Group. Look
AHEAD (Action for Health in Diabetes):
design and methods for a clinical trial of
weight loss for the prevention of cardio-
vascular disease in type 2 diabetes. Con-
trol Clin Trials 2003;24:610–628
5. Look AHEAD Research Group, Pi-Sunyer
X, Blackburn G, Brancati FL, Bray GA,
Bright R, Clark JM, Curtis JM, Espeland
MA, Foreyt JP, Graves K, Haffner SM,
Harrison B, Hill JO, Horton ES, Jakicic J,
Jeffery RW, Johnson KC, Kahn S, Kelley
DE, Kitabchi AE, Knowler WC, Lewis
CE, Maschak-Carey BJ, Montgomery B,
Nathan DM, Patricio J, Peters A, Redmon
JB, Reeves RS, Ryan DH, Safford M, Van
Dorsten B, Wadden TA, Wagenknecht L,
Wesche-Thobaben J, Wing RR, Yanovski
SZ. Reduction in weight and cardiovascu-
lar disease risk factors in individuals with
type 2 diabetes: one-year results of the
Look AHEAD trial. Diabetes Care 2007;
30:1374–1383
6. American Diabetes Association. Stan-
dards of medical care in diabetes: 2009.
Diabetes Care 2009;32:S13–S61
7. Franz MJ. 2002 diabetes nutrition recom-
mendations: grading the evidence. Diabe-
tes Educ 2002;28:756–759, 762–764,
766
8. Lichtenstein AH, Appel LJ, Brands M,
Carnethon M, Daniels S, Franch HA,
Franklin B, Kris-Etherton P, Harris WS,
HowardB,KaranjaN,LefevreM,RudelL,
Sacks F, Van Horn L, Winston M, Wylie-
Rosett J. Summary of American Heart Asso-
ciationDietandLifestyleRecommendations
revision 2006. Arterioscler Thromb Vasc
Biol 2006;26:2186–2191
9. Hu FB, Cho E, Rexrode KM, Albert CM,
Manson JE. Fish and long-chain ome-
ga-3 fatty acid intake and risk of coro-
nary heart disease and total mortality in
diabetic women. Circulation 2003;107:
1852–1857
10. Harris WS. n-3 fatty acids and serum li-
poproteins: human studies. Am J Clin
Nutr 1997;65(Suppl. 5):1645S–1654S
11. Saito Y, Yokoyama M, Origasa H, Matsu-
zakiM,MatsuzawaY,IshikawaY,Oikawa
S, Sasaki J, Hishida H, Itakura H, Kita T,
Kitabatake A, Nakaya N, Sakata T, Shi-
mada K, Shirato K; the JELIS Investiga-
tors, Japan. Effects of EPA on coronary
artery disease in hypercholesterolemic
patients with multiple risk factors: sub-
analysis of primary prevention cases
from the Japan EPA Lipid Intervention
Study (JELIS). Atherosclerosis 2008;200:
135–140
12. Mozaffarian D, Lemaitre RN, Kuller LH,
Burke GL, Tracy RP, Siscovick DS; the
Cardiovascular Health Study. Cardiac
beneﬁts of ﬁsh consumption may depend
on the type of ﬁsh meal consumed: the
Cardiovascular Health Study. Circulation
2003;107:1372–1377
Belalcazar and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 1, JANUARY 2010 199